Add to Favorites
Test Description

There are key genes that are recurrently mutated in various human cancers. Genomic DNA is isolated from bone marrow, aspirates, peripheral blood or formalin fixed paraffin embedded tissue and the DNA sequence of targeted regions of 236 genes: ABL1, ABL2, AKT1, AKT2, AKT3, ALK, APC, AR, ARAF, ARHGEF1, ARID1A, ARID2, ASXL1, ATM, ATRX, AXL, B2M, BAP1, BCL2, BCL2L11, BCL6, BCOR, BIRC3, BRAF, BRCA1, BRCA2, BTK, CALR, CARD11, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD33, CD79A, CD79B, CDH1, CDK2, CDK4, CDK6, CDKN1B, CDKN2A, CDKN2B, CEBPA, CHD1, CHEK2, CIC, CIITA, CREBBP, CRLF2, CSF1R, CSF3R, CTCF, CTNNB1, CXCR4, DAXX, DDR2, DDX3X, DDX41, DIS3, DNMT3A, EBF1, EGFR, EGR1, EIF1AX, EP300, EPCAM, EPHA2, EPOR, ERBB2, ERBB3, ERBB4, ESR1, ETNK1, ETV6, EWSR1, EZH2, FAM46C, FAS, FAT1, FBXW7, FGF19, FGFR1, FGFR2, FGFR3, FLT1, FOXO1, FUBP1, GAB2, GATA2, GATA3, GNA11, GNA13, GNAI2, GNAQ, GNAS, GNB1, H3F3A, HIF1A, HIST1H1E, HNF1A, HRAS, ID3, IDH1, IDH2, IGF1R, IKBKB, IKZF1, IKZF3, IRAK4, ITPKB, JAK1, JAK2, JAK3, KDR, KEAP1, KIT, KLF2, KRAS, MALT1, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K14, MAP3K9, MAPK1, MCL1, MDM2, MDM4, MED12, MEF2B, MET, MITF, MLH1, KMT2D, MPL, MSH2, MSH6, MTOR, MYC, MYCN, MYD88, NF1, NF2, NFKBIE, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK2, NTRK3, P2RY8, PALB2, PBRM1, PDGFRA, PDGFRB, PHF6, PIK3CA, PIK3CD, PIK3R1, PIM1, PLCG1, PLCG2, PMS2, POLE, POT1, PPM1D, PRDM1, PRPS1, PTCH1, PTEN, PTPN11, RAC1, RAD21, RB1, REL, RET, RHEB, RHOA, RICTOR, RIPK1, RIT1, RNF43, ROS1, RPS15, RUNX1, S1PR2, SAMHD1, SETBP1, SETD2, SF3B1, SGK1, SH2B3, SMAD4, SMARCB1, SMC1A, SMC3, SMO, SOCS1, SOX2, SPEN, SPOP, SRSF2, STAG2, STAT3, STAT5B, STAT6, STK11, TBL1XR1, TCF3, TERT, TET2, TGFBR1, TGFBR2, TLR2, TNFAIP3, TNFRSF14, TP53, TRAF2, TRAF3, TSC1, TSC2, U2AF1, UBR5, VHL, WT1, XPO1, ZFHX4, ZMYM3, and ZRSR2, is determined using next-generation sequencing (NGS) technology.

Clinical Significance

For predictive and prognostic purposes.

NexCourse Complete is a multi-gene molecular profiling assay covering genes implicated in the pathogenesis of solid and/or hematological malignancies. The results may provide insight into the pathobiology of the malignancy, aid in risk assessment, and identify potential therapeutic options and clinical trials based on molecular drivers.

Specimen Requirements
  • Peripheral blood: 2-3 mL in EDTA (purple-top) tube
  • Bone marrow: 2-3 mL in EDTA (purple-top) tube
  • Tissue (Preferred): Two (2) formalin-fixed, paraffin-embedded tissue/ fine needle aspirate (FFPE/FNA) blocks containing tumor tissue from recent surgery or biopsy or sixteen (16) 2x5 µm sections with accompanying H&E slide.
  • Acceptable Alternative: One (1) formalin-fixed, paraffin-embedded tissue/fine needle aspirate (FFPE/FNA) block containing tumor tissue from recent surgery or biopsy or eight (8) 2×5 µm sections with accompanying H&E slide.
  • Unacceptable: Specimens preserved in alternative (non-formalin) fixatives, decalcified specimens, fresh or frozen tissue.
Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. DO NOT FREEZE.

CPT Code(s)*
Medicare MolDX CPT Code(s)*
Turnaround Time

12 Days

New York Approved
Level of Service

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.